Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "Clinical"

3639 News Found

Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial
Clinical Trials | June 01, 2026

Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial

This marks one of the most closely watched oncology readouts at this year’s medical congress


International scientists say deuterium research could reshape medicine
R&D | June 01, 2026

International scientists say deuterium research could reshape medicine

The conference highlighted research suggesting that deuterium levels may influence key biological processes


Oval Fertility launches in Hyderabad, introduces Astec Chronos AI-powered IVF tech to India
Healthcare | June 01, 2026

Oval Fertility launches in Hyderabad, introduces Astec Chronos AI-powered IVF tech to India

Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys


Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
R&D | May 31, 2026

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease


Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting
Drug Approval | May 30, 2026

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial


Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial
Clinical Trials | May 30, 2026

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer


AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial
Clinical Trials | May 30, 2026

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis


FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough
R&D | May 30, 2026

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term


FDA delays AstraZeneca decision on camizestrant as regulators seek more data
Drug Approval | May 30, 2026

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial


Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial
News | May 29, 2026

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors